LONDON, May 21, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Chiltern has been recognized with a CRO Leadership Award in all five categories: Quality, Reliability, Accessibility, Productivity and Regulatory. The awards are given by Life Science Leader publication based on the data-driven research of Nice Insight.
Glenn Kerkhof, Chiltern CEO, stated, "Chiltern is delighted to be recognized as a CRO leader in the Quality, Reliability, Accessibility, Productivity and Regulatory categories. Chiltern has been serving clients with pride for 30 years and has established a track record around the world as an expert, efficient and highly responsive full service CRO. It is a privilege to be recognized by members of the pharmaceutical industry that we serve and a great pleasure to accept this award on behalf of all of the people at Chiltern."
"On a quarterly basis, Nice Insight conducts a pharmaceutical and biotechnology survey, which is deployed to 40,000 outsourcing-facing biotech and pharma executives," explained Rob Wright, Chief Editor, Life Science Leader. "Nice Insight then aggregates a year's worth of data to determine which companies rank in the top quartile for each of the attributes to determine award winners. The winners should be proud of these awards because they were determined by data gathered from customers."
Company profileAbout Chiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,300 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides
Copyright©2010 PR Newswire.
All rights reserved